Most Popular
-
1
Actor Jung Woo-sung admits to being father of model Moon Ga-bi’s child
-
2
Wealthy parents ditch Korean passports to get kids into international school
-
3
Man convicted after binge eating to avoid military service
-
4
First snow to fall in Seoul on Wednesday
-
5
Final push to forge UN treaty on plastic pollution set to begin in Busan
-
6
Korea to hold own memorial for forced labor victims, boycotting Japan’s
-
7
Nvidia CEO signals Samsung’s imminent shipment of AI chips
-
8
Industry experts predicts tough choices as NewJeans' ultimatum nears
-
9
Job creation lowest on record among under-30s
-
10
Opposition chief acquitted of instigating perjury
[DISCLOSURE] Yuhan Corp. (000100) announced on July 28 that it has signed a technology transfer deal with China’s Luoxin Biotechonology for YH25448, a new targeted therapy for lung cancer.
The firm will receive an upfront payment of US$6 million and subsequent milestone payments that amount up to US$120 million.
The firm will receive an upfront payment of US$6 million and subsequent milestone payments that amount up to US$120 million.
